Toggle navigation
Wellington Partners
Home
Team
Approach
Portfolio
News
Contact
Enter Part of Title
Display #
5
10
15
20
25
30
50
100
All
Themis receives FDA fast track designation for Chikungunya vaccine candidate
Themis starts Phase II clinical study of Chikungunya vaccine in endemic area
Themis starts Phase II trial of Chikungunya vaccine in the U.S.
Themis vector technology featured in quest for Zika vaccine by Top EU-groups
Themis Zika Vaccine Developement receives 1 Mio GBP Boost
Themis: Chikungunya vaccine development towards Phase III trials receives £ 3 Mio. boost by Innovate UK
TRiCares closes €22 million Series B financing round
UroMems appoints medical device industry leader Steffen Hovard to Board of Directors
UroMems Completes €23 Million Series B Financing
UroMems wins prestigious Prix Galien Med’Start-Up for best collaboration in the medtech or digital sector
US patent grants strengthen SNIPR BIOME’s approach to enhance immuno-oncology outcomes by microbiome modulation
Wellington invests in SIRS Therapeutics to develop FX06 for treatment of ARDS in COVID-19 patients in collaboration with F4 Pharma
Wellington Partners co-leads €30 million Series A financing in Confo Therapeutics
Wellington Partners participates in $100 Million Series B financing at eGenesis
Wellington Partners participates in $53 Million Series B financing at ImCheck
Wellington Partners’s portfolio company Themis to be acquired by MSD
Page 5 of 5
Start
Prev
1
2
3
4
5
Next
End